GE HealthCare Technologies (NASDAQ:GEHC) Stock Gets Price Target Increase from Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised GE HealthCare’s price target from $80 to $90 and maintained an “outperform” rating, implying 17.76% upside from the prior close.
• Analyst sentiment remains favorable: GEHC has a consensus “Moderate Buy” rating, with 12 Buy ratings and 11 Holds, and an average price target of $79.91.
• GE HealthCare exceeded quarterly expectations, reporting adjusted EPS of $1.34 versus a $1.20 consensus and revenue of $5.51 billion, up 7.2% year over year.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) had its target price increased by research analysts at Royal Bank Of Canada from $80.00 to $90.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Royal Bank Of Canada's price objective suggests a potential upside of 17.76% from the stock's previous close.

A number of other equities analysts have also commented on the company. Weiss Ratings raised GE HealthCare Technologies from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, October 6th. Oppenheimer reiterated an "outperform" rating on shares of GE HealthCare Technologies in a research note on Thursday, July 30th. Needham & Company LLC reissued a "buy" rating and set a $93.00 price objective on shares of GE HealthCare Technologies in a report on Monday, October 5th. BTIG Research upped their price target on GE HealthCare Technologies from $75.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, UBS Group increased their price target on shares of GE HealthCare Technologies from $67.00 to $73.00 and gave the stock a "neutral" rating in a report on Friday, July 31st. Twelve equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $79.91.

GE HealthCare Technologies Stock Performance

Shares of NASDAQ GEHC traded up $0.60 during midday trading on Thursday, hitting $76.42. The company's stock had a trading volume of 2,937,484 shares, compared to its average volume of 4,233,028. The stock has a fifty day moving average price of $68.37 and a 200 day moving average price of $70.17. GE HealthCare Technologies has a one year low of $58.75 and a one year high of $89.77. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $34.52 billion, a price-to-earnings ratio of 17.55, a P/E/G ratio of 1.89 and a beta of 0.73.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.20 by $0.14. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same period last year, the firm earned $1.07 EPS. GE HealthCare Technologies's revenue for the quarter was up 7.2% on a year-over-year basis. On average, research analysts forecast that GE HealthCare Technologies will post 4.93 EPS for the current fiscal year.

Institutional Trading of GE HealthCare Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in GE HealthCare Technologies during the 3rd quarter valued at about $21,123,000. ProShare Advisors LLC grew its position in shares of GE HealthCare Technologies by 2.8% during the 3rd quarter. ProShare Advisors LLC now owns 518,028 shares of the company's stock worth $33,863,000 after buying an additional 14,052 shares during the period. Vise Technologies Inc. grew its position in shares of GE HealthCare Technologies by 2.3% during the 3rd quarter. Vise Technologies Inc. now owns 10,807 shares of the company's stock worth $706,000 after buying an additional 243 shares during the period. Americana Partners LLC raised its stake in shares of GE HealthCare Technologies by 9.2% during the third quarter. Americana Partners LLC now owns 4,169 shares of the company's stock worth $273,000 after buying an additional 350 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in GE HealthCare Technologies by 334.2% in the third quarter. International Assets Investment Management LLC now owns 50,000 shares of the company's stock valued at $3,268,000 after buying an additional 38,485 shares during the period. Institutional investors own 82.06% of the company's stock.

Key GE HealthCare Technologies News

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Quarterly earnings beat expectations: GEHC reported third-quarter adjusted EPS of $1.34, versus the $1.20–$1.21 analyst consensus, while revenue of $5.51 billion exceeded estimates of approximately $5.35 billion and increased 7.2% year over year. GE HealthCare reports third quarter 2026 financial results
• Positive Sentiment: Guidance was raised: Management increased its 2026 outlook, including organic revenue growth of about 4%, adjusted EPS of $4.95–$5.05 and free cash flow of at least $1.6 billion. Broad-based demand, stronger margins and healthy hospital spending contributed to the upgrade. GE HealthCare lifts forecasts on healthy hospital spending
• Positive Sentiment: Growth initiatives strengthen the outlook: Analysts highlighted 6.2% organic growth, margin expansion, Pharmaceutical Diagnostics, the Flyrcado product and the SOFIE acquisition as potential drivers of future revenue and radiopharmaceutical growth. GE HealthCare Q3 broad-based growth makes the bull case more compelling
• Positive Sentiment: Analyst targets moved higher: Mizuho raised its price target to $90 from $85, BNP Paribas increased its target to $100 from $96, and BTIG lifted its target to $83 from $75 while maintaining a buy rating. Mizuho Securities adjusts GE HealthCare price target
• Neutral Sentiment: A comparison with Haemonetics discusses GEHC’s relative value appeal among medical-products stocks, but does not introduce a material new company-specific catalyst. GEHC versus HAE value comparison
• Negative Sentiment: Jeannette Bankes, president and CEO of Patient Care Solutions, is leaving to become CEO of another company. The leadership transition is a modest uncertainty, although it was overshadowed by the earnings beat. GE HealthCare shares rise on higher results and outlook upgrade

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company's portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.